NASDAQ: PGNYProgyny Inc Stock
$34.21+0.96 (+2.89%)
Updated Sep 26, 2023
PGNY Price
$34.21
Fair Value Price
$35.76
Market Cap
$3.26B
52 Week Low
$28.03
52 Week High
$45.98
P/E
64.55x
P/B
6.95x
P/S
3.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$957.46M
Earnings
$49.29M
Gross Margin
21.9%
Operating Margin
4.9%
Profit Margin
5.1%
Debt to Equity
0.45
Operating Cash Flow
$169M
Beta
1.4
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PGNY Overview
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PGNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PGNY ($34.21) is undervalued by 4.34% relative to our estimate of its Fair Value price of $35.76 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PGNY ($34.21) is not significantly undervalued (4.34%) relative to our estimate of its Fair Value price of $35.76 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PGNY is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PGNY due diligence checks available for Premium users.
Be the first to know about important PGNY news, forecast changes, insider trades & much more!
PGNY News
Valuation
PGNY fair value
Fair Value of PGNY stock based on Discounted Cash Flow (DCF)
Price
$34.21
Fair Value
$35.76
Undervalued by
4.34%
PGNY ($34.21) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PGNY ($34.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PGNY is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PGNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
64.55x
Industry
55.14x
Market
14.06x
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PGNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.95x
Industry
3.07x
PGNY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PGNY's financial health
Profit margin
Revenue
$279.4M
Net Income
$15.0M
Profit Margin
5.4%
PGNY's Earnings (EBIT) of $46.89M... subscribe to Premium to read more.
Interest Coverage Financials
PGNY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$681.5M
Liabilities
$212.0M
Debt to equity
0.45
PGNY's short-term assets ($561.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PGNY's short-term assets ($561.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PGNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$76.0M
Investing
-$58.9M
Financing
-$1.8M
PGNY's operating cash flow ($169.38M)... subscribe to Premium to read more.
Debt Coverage Financials
PGNY vs Health Information Service Stocks
Progyny Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.